Table 4 Difficulties in the clinical practice guidelines development process (N = 265)
Publication period | P a | |||||
|---|---|---|---|---|---|---|
by 2005 | 2006–2010 | 2011–2015 | 2016–2019 | |||
(N = 40) | (N = 47) | (N = 77) | (N = 101) | |||
Composing development group | n (%) | 10 (25.6) | 9 (20.5) | 33 (42.9) | 45 (45.5) | 0.003 |
Searching for the research evidence | n (%) | 9 (23.1) | 8 (20.5) | 36 (46.8) | 47 (47.5) | 0.001 |
Evaluating the evidence | n (%) | 21 (53.8) | 22 (50.0) | 45 (58.4) | 60 (60.6) | 0.285 |
Handling with parts without evidence | n (%) | 20 (51.3) | 27 (61.4) | 53 (68.8) | 65 (65.7) | 0.128 |
Coping with the paucity of Japanese evidence | n (%) | 27 (69.2) | 30 (68.2) | 40 (51.9) | 37 (37.4) | < 0.001 |
Editing | n (%) | 20 (51.3) | 22 (50.0) | 36 (46.8) | 51 (51.5) | 0.958 |
Coordinating with other organizations | n (%) | 6 (15.4) | 4 (9.1) | 10 (13.0) | 19 (19.2) | 0.295 |
Resolving misunderstanding on standardization and EBM | n (%) | 12 (30.8) | 9 (20.9) | 9 (11.7) | 20 (20.2) | 0.209 |
Securing funds | n (%) | 8 (20.5) | 6 (13.6) | 13 (16.9) | 19 (19.2) | 0.869 |
Getting support from CPG experts | n (%) | 5 (12.8) | 0 (0.0) | 15 (19.5) | 14 (14.1) | 0.229 |